secwatch.observer — SEC 8-K summary ====================================== Issuer: Drugs Made In America Acquisition II Corp. (DMII) CIK: 0002040475 Form: 8-K Filed at: 2026-11-18T16:08:56+00:00 Accession: 0001477932-26-007137 Event type: m_and_a Sentiment: positive Materiality: 0.70 Item codes: 2.03, 8.01, 9.01 LLM model: deepseek-v4.1-flash:cloud@v2 DMII proposes $600M combination with Alpha AI Biotech paid in 60M shares at $10.00 -------------------------------------------------------------------------------- - Preliminary, nonbinding proposal values Alpha AI Biotech Group at $600 million pre-money, payable in 60,000,000 ordinary shares at $10.00 per share. - Up to 30,000,000 additional earn-out shares in two equal tranches tied to share-price thresholds of $12.50 and $15.00 during 24 months after closing. - Board approved a 30-day limited standstill expiring on or about December 3, 2026; no definitive agreement, due diligence and audited financials still pending. - Investor Tal Alpha funded $250,000 on November 6, 2026; notes consolidated into a $700,000 convertible note maturing June 30, 2027, convertible at a 35% discount; $700,000 remains available. - Alon Izidor Tal, CEO of the Investor, is also an Alpha director and acknowledged the proposal on Alpha's behalf. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/2040475/000147793226007137/0001477932-26-007137-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/2040475/000147793226007137/dmiiu_8k.htm HTML page: https://secwatch.observer/filing/0001477932-26-007137 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer